Effect of dipyridamole during acute stroke: exploring antithrombosis and neuroprotective benefits.
Currently, many stroke-prone individuals take antithrombotic drugs, which have known antiplatelet properties, to decrease stroke incidence. There is now evidence that this regimen could also reduce stroke severity through neuroprotective, nonplatelet mechanisms that include anti-inflammatory processes. Inflammation was found to play an important role in atherosclerosis/thrombosis development and acute stroke progression. In light of these findings, prevention strategies that target inflammatory mediators are under investigation. A common secondary stroke prevention therapeutic, dipyridamole, has shown promise for reducing stroke recurrence without increasing bleeding. In addition to its antiplatelet ability, dipyridamole has positive effects on vascular endothelium and inflammation. This review explores the effect of dipyridamole during acute stroke, revealing its potential use for improving poststroke clinical outcome.
Department of Medical Biophysics, The University of Western Ontario, London, Ontario, Canada. cdesterr@uwo.ca
C D
CD
d'Esterre
T-Y
TY
Lee
D000818:Animals; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004176:Dipyridamole / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy / Q000503:physiopathology; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011817:Rabbits; D012008:Recurrence; D020521:Stroke / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control
D005343:Fibrinolytic Agents; D018696:Neuroprotective Agents; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole